CharActeristics, sizing anD outcomes of stenotic, tapered, rapHe-type bicuspid aOrtic valves treated with trans-catheter device implantation: Insights the AD HOC registry
Andrea Buono,Chiara De Biase,Tommaso Fabris,Michele Bellamoli,Won-Keun Kim,Nicholas Montarello,Giuliano Costa,Andrea Zito,Mesfer Alfadhel,Ofir Koren,Simone Fezzi,Barbara Bellini,Mauro Massussi,Andrea Scotti,Lin Bai,Giulia Costa,Alessandro Mazzapicchi,Enrico Giacomin,Riccardo Gorla,Alessia Latini,Chiara Fraccaro,Lars Sondergaard,Orazio Strazzieri,Mauro Boiago,Marco Busco,Efstratios Charitos,Ady Orbach,Antonio Messina,Luca Bettari,Edoardo Navazio,Donato Antonio Paglianiti,Takashi Nagasaka,Massimo Napodano,Emmanuel Villa,Marco Angelillis,Alfonso Ielasi,Uri Landes,Nedy Brambilla,Francesco Bedogni,Antonio Mangieri,Francesco Saia,Luca Favero,Mao Chen,Marianna Adamo,Azeem Latib,Anna Sonia Petronio,Matteo Montorfano,Raj R Makkar,Darren Mylotte,Daniel J Blackman,Marco Barbanti,Ole De Backer,Didier Tchètchè,Diego Maffeo,Giuseppe Tarantini
DOI: https://doi.org/10.1016/j.ijcard.2024.132569
2024-12-15
Abstract:Background: Raphe-type bicuspid aortic valve (BAV) is a potential hostile scenario in trans-catheter aortic valve replacement (TAVR) due to pronounced calcium burden, possibly associated with tapered valve configuration. Trans-Catheter heart valve (THV) sizing strategy (annular vs. supra-annular) is controversial in this valve subtype. Objectives: To describe the phenotypical characteristics of severe, tapered, raphe-type, BAV stenosis undergoing TAVR and to explore safety and efficacy of modern-generation THVs, analysing the impact of annular and supra-annular sizing strategies on short- and mid-terms outcomes. Methods: This is a retrospective, multicenter registry enrolling consecutive stenotic Sievers type 1 BAV treated with TAVR. Study population was divided into tapered and non-tapered configuration according to MSCT analysis. Matched comparison between annular and supra-annular sizing groups was performed in tapered population. Results: From January 2016 to June 2023, 897 patients were enrolled. Of them, 696 patients displayed a tapered configuration. Of those, 510 received a THV according to annular sizing. After propensity score matching 186 matched pairs were selected. Technical success (96.2 % vs 94.1 %, OR 1.61 [0.61-4.24], p = 0.34), 30-day device success (83.6 % in both groups, OR 1.42 [0.78-2.57], p = 0.25) and 30-day early safety (71.8 % vs 70.5 %, OR 1.07 [0.68-1.68], p = 0.78) were similar between the annular and supra-annular sizing groups; a higher post-TAVR gradient was observed in supra-annular group, although it was only 2 mmHg mean. At mid-term follow-up, the rate of clinical efficacy was 84.7 %. Conclusions: TAVR with modern-generation devices is safe and effective for tapered raphe-type BAV, showing comparable results for annular and supra-annular sizing strategies.